Torrent Pharmaceuticals Limited

Equities

TORNTPHARM

INE685A01028

Pharmaceuticals

Market Closed - Bombay S.E. 06:01:01 2024-07-23 EDT 5-day change 1st Jan Change
3,137.15 INR +3.58% Intraday chart for Torrent Pharmaceuticals Limited +6.30% +36.10%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Transcript : Torrent Pharmaceuticals Limited, Q1 2025 Earnings Call, Jul 23, 2024
Torrent Pharmaceuticals Limited Announces Promotion of Ashish Hajarnis as Executive Director from Vice President CI
Torrent Pharmaceuticals Limited Reports Earnings Results for the First Quarter Ended June 30, 2024 CI
Bain-backed Emcure Pharma's $234 million India IPO draws $11 billion in bids RE
Takeda gives Sun Pharma, Cipla rights to commercialize gastro drug in India RE
Torrent Pharma Signs Deal with Japan's Takeda to Market Acid-Related Disorders Drug in India MT
Torrent Pharmaceuticals Enters into Non-Exclusive Patent Licensing Agreement with Takeda Pharmaceuticals to Commercialize Its Novel Gastrointestinal Drug in India CI
Jefferies Adjusts Torrent Pharmaceuticals’ Price Target to INR3,070 From INR2,930, Keeps at Buy MT
INDIA STOCKS-Indian shares at record highs, boosted by pharma stocks, Adani Ports RE
Torrent Pharmaceuticals' Consolidated Profit Jumps in Fiscal Q4; EPS Tops Estimates MT
Torrent Pharmaceuticals to Raise Up to INR50 Billion via Qualified Institutional Placement MT
Torrent Pharma Board Approves to Raise INR 50,000 Million CI
Torrent Pharmaceuticals Limited Announces Stepping Down of Jinesh Shah as the Director, Effective from 23 July 2024 CI
Torrent Pharmaceuticals Limited Recommends Final Dividend for the Financial Year Ended 31 March, 2024, Payable on or Around 31 July, 2024 CI
Transcript : Torrent Pharmaceuticals Limited, Q4 2024 Earnings Call, May 24, 2024
Torrent Pharmaceuticals Limited Reports Earnings Results for the Full Year Ended March 31, 2024 CI
Torrent Pharmaceuticals Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2024 CI
Promoter group to sell stake worth $316 million in India's Cipla, CNBC-TV18 reports RE
Torrent Pharmaceuticals Limited Receives Communication for Collection of Penalty from Deputy Commissioner of State Tax Ghaziabad, Uttar Pradesh CI
Torrent Pharmaceuticals Limited Receives an Order from Deputy Commissioner of State Tax, Guwahati -A-99, Guwahati, Assam, Imposing a Penalty of INR 3,39,842 CI
Torrent Pharmaceuticals Limited Receives Order from Deputy Commissioner State Tax, Special Circle 1, Kunchanapalli, Andhra Pradesh CI
Torrent Pharmaceuticals Limited Receives Order Passed by Deputy Commissioner of State Tax, Ropar Division, Punjab Imposing Penalty CI
Torrent Pharmaceuticals Limited Receives an Order Passed Under Section 73 of the Goods and Service Act, 2017, Imposing A Penalty of INR 388,809.60 CI
Torrent Pharmaceuticals Limited Announces Change in Directorate , Effective 31 March 2024 CI
Torrent Pharmaceuticals Limited Announces Superannuation of Ashok Modi as Executive Director CI
Chart Torrent Pharmaceuticals Limited
More charts
Logo Torrent Pharmaceuticals Limited
Torrent Pharmaceuticals Limited is an India-based pharmaceutical company. The Company is focused on various therapeutic segments, such as cardiovascular (CV), central nervous system (CNS), gastrointestinal (GI), vitamins minerals nutrients (VMN), anti-diabetes (AD), pain, gynecology, and dermatology. The Company is engaged in research, development, manufacturing, marketing and distribution of branded and generic pharmaceutical formulations in India and internationally. Its pediatric product brands include Tedibar, Atogla, Spoo and B4 Nappi. Its acne/facecare products brands include Clinmiskin, ACNEMOIST, TRACNILO and fash. The Company's hair/scalp care products brands include Proanagen, Perlice, Permite and NOSKURF. Its manufacturing facilities are located in the states of Gujarat, Himachal Pradesh, Madhya Pradesh, Andhra Pradesh and Sikkim. The Company's primary channel of distribution is through the wholesale drug distributors, stockiest and retail pharmacies.
Employees
15,718
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
30
Last Close Price
3,137.15INR
Average target price
2,932.40INR
Spread / Average Target
-6.53%
Consensus
  1. Stock Market
  2. Equities
  3. TORNTPHARM Stock
  4. News Torrent Pharmaceuticals Limited
  5. Torrent Pharma Signs Deal with Japan's Takeda to Market Acid-Related Disorders Drug in India